Skip to content
HowShorted

Emergent Biosolutions, Inc. short interest in 2020

In 2020, Emergent Biosolutions, Inc.'s disclosed short interest ran from 5.05% of shares outstanding on 15 Jan 2020 to 5.05% on 31 Dec 2020, a change of +0.00 percentage points. The year's high was 5.31% on 15 Jul 2020 and its low 3.72% on 13 Nov 2020, averaging 4.58% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.06 days on 31 Jan 2020. Full history: Emergent Biosolutions, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Emergent Biosolutions, Inc. in 2020

2020 in figures

Start of year
5.05% (15 Jan 2020)
End of year
5.05% (31 Dec 2020)
Change
+0.00 pp
High
5.31% (15 Jul 2020)
Low
3.72% (13 Nov 2020)
Average
4.58%
Highest days to cover
12.06 (31 Jan 2020)
SEC filings marked
9

Every report in 2020

Emergent Biosolutions, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20205.05%8.43results (8-K)
31 Jan 20204.97%12.06
14 Feb 20204.69%9.68
28 Feb 20204.22%4.03results (8-K), 10-K filed
13 Mar 20204.34%4.59
31 Mar 20204.64%3.99
15 Apr 20204.69%7.17
30 Apr 20204.43%3.91results (8-K)
15 May 20204.64%5.0010-Q filed
29 May 20205.03%6.08
15 Jun 20205.11%3.01
30 Jun 20205.24%4.76
15 Jul 20205.31%5.74
31 Jul 20204.93%1.5610-Q filed, results (8-K)
14 Aug 20204.86%2.52
31 Aug 20204.74%5.15
15 Sep 20204.67%4.12
30 Sep 20204.14%4.59
15 Oct 20203.81%2.71
30 Oct 20203.99%4.76
13 Nov 20203.72%3.61results (8-K), 10-Q filed
30 Nov 20203.80%4.07
15 Dec 20203.90%4.72
31 Dec 20205.05%4.44

See also: Emergent Biosolutions, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.